About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Denver | 18,161 Studies Near You | Clareo Health

Clinical Trials LocationsDenver

Clinical Trials in Denver

Discover 18,161 clinical trials near Denver, Colorado. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 17361-17380 of 18,161 trials

COMPLETEDPhase 2< 1 mile

Study in Patients With Asthma

NCT00215358

The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control drug.

Dey32 participantsStarted Jul 2002

Denver, Colorado, United States • Medford, Oregon, United States

COMPLETEDPhase 3< 1 mile

Study in Patients With COPD

NCT00215449

The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.

Dey690 participants

Bessemer, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +65 more locations

Find Trials by Condition in Denver

Breast Cancerin Denver Lung Cancerin Denver Prostate Cancerin Denver Colorectal Cancerin Denver Melanomain Denver Leukemiain Denver Lymphomain Denver Pancreatic Cancerin Denver Ovarian Cancerin Denver Brain Cancerin Denver Diabetesin Denver

Data from ClinicalTrials.govTerms

COMPLETEDPhase 3< 1 mile

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD

NCT00280371

The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.

Dey345 participantsStarted Jan 2006

Jasper, Alabama, United States • Phoenix, Arizona, United States • Buena Park, California, United States +49 more locations

COMPLETEDPhase 3< 1 mile

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD

NCT00215436

The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.

Dey345 participantsStarted Mar 2005

Jasper, Alabama, United States • Phoenix, Arizona, United States • Tuscon, Arizona, United States +41 more locations

TERMINATEDPhase 3334 miles

GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes

NCT00229710

This is a 140-week open-label, multi-center long-term extension study from GALLANT 9 to monitor the safety and tolerability of oral tesaglitazar 0.5 mg and insulin in patients with type 2 diabetes during up to 140 weeks of treatment. The total duration, including treatment and follow-up, is 143 weeks.

Diabetes Mellitus, Type 2

AstraZeneca270 participantsStarted Feb 2005

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +66 more locations

TERMINATEDPhase 3371 miles

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

NCT00226330

This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.

Diabetes Mellitus, Type 2

AstraZeneca1,100 participantsStarted Mar 2005

Birmingham, Alabama, United States • Columbiana, Alabama, United States • Mobile, Alabama, United States +168 more locations

COMPLETEDPhase 2371 miles

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00429091

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity DisorderADHD

Abbott243 participantsStarted Jan 2007

San Francisco, California, United States • Wildomar, California, United States • Orlando, Florida, United States +19 more locations

COMPLETEDPhase 3446 miles

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes

NCT00487240

The purpose of this study is to examine the efficacy and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime insulin therapy in patients with type 1 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives.

Diabetes Mellitus, Type 1

Eli Lilly and Company387 participantsStarted Jun 2007

Idaho Falls, Idaho, United States • Springfield, Illinois, United States • Topeka, Kansas, United States +25 more locations

COMPLETEDPhase 4487 miles

Esomeprazole for Treatment of GERD in Pediatric Patients

NCT00228527

To look at the safety and improvement in symptoms of a once a day dosing of esomeprazole in children 1 to 11 years old with inflammation of their esophagus or food pipe ("esophagitis") caused by gastroesophageal reflux disease (GERD) and diagnosed by endoscopy. To verify the healing of the esophageal inflammation if the endoscopy reveals cuts in the lining of the food pipe. To collect information that will describe the psychological, social, and economic effects on the primary caregiver of raising children ages 1 to 5 years old with GERD.

Gastroesophageal Reflux Disease (GERD)Erosive EsophagitisNon-erosive Esophagitis

AstraZeneca100 participantsStarted Oct 2004

Mobile, Alabama, United States • Phoenix, Arizona, United States • Wilmington, Delaware, United States +33 more locations

COMPLETEDNA487 miles

PREFER (Pacemaker Remote Follow-Up Evaluation and Review)

NCT00294645

The purpose of the study is to compare remote pacemaker follow-up to current standard of care follow-up. The study will compare the rate of first diagnosis of clinically actionable events between patients who utilize the Medtronic Carelink® Network (Remote arm) versus patients who are followed via routine office visits augmented by transtelephonic monitoring (TTM)(Control arm).

BradycardiaArrhythmia

Medtronic Cardiac Rhythm and Heart Failure980 participantsStarted Apr 2004

Scottsdale, Arizona, United States • Little Rock, Arkansas, United States • Washington D.C., District of Columbia, United States +42 more locations

COMPLETEDPhase 4491 miles

Acid-Associated Heartburn Symptoms and Dose of Esomeprazole

NCT00206024

This is a multi-center, double-blind, parallel-group, randomized, proof of concept trial to investigate the relationship between dose of esomeprazole magnesium and acid-associated heartburn symptoms during 4 weeks of treatment. The safety and tolerability of esomeprazole magnesium in doses up to 40 mg BID will also be assessed.

AstraZeneca330 participantsStarted Nov 2004

Tucson, Arizona, United States • Anaheim, California, United States • Orange, California, United States +24 more locations

COMPLETEDPhase 3586 miles

Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients

NCT00241501

This study is a phase III, multi-centre, randomized, double-blind study to assess the safety and tolerability of once daily treatment with esomeprazole 20 or 40 mg in pediatric and adolescent patients 12 to 17 years of age, inclusive, with clinically diagnosed GERD. The treatment period will be up to 8 weeks.

Gastroesophageal Reflux Disease (GERD)

AstraZeneca140 participantsStarted Feb 2004

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Wilmington, Delaware, United States +37 more locations

TERMINATEDPhase 1586 miles

A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)

NCT00683553

This is a Phase 1, randomized, double-blind, dose escalation, safety and pharmacokinetic study. The study will be conducted in approximately 10 sites in the United States. Up to 48 patients at high risk for AKI (CCF score ≥ 5 OR an estimated GFR (eGFR) \<60 mL/min/1.73 m2) who have undergone major cardiovascular surgery will participate. Patients will receive a single IV injection of I5NP or placebo following cardiovascular surgery. I5NP will be administered 4 hours (+/- 30 minutes) following removal of the cardiopulmonary bypass machine (CBM). The duration of the study is approximately 44 days, inclusive of a 14 day screening period. Patients will be contacted by phone at 6 and 12 months for follow-up questions. Patient visits are screening, day of surgery, hospital in-patient Days 1, 2, 3 - 5 and Day 7 or hospital discharge. Safety follow-up will continue until 30 days post-surgery. 2 phone calls will be made at 6 and 12 months after date of surgery.

Acute Renal FailureAcute Kidney Injury

Quark Pharmaceuticals3 participantsStarted May 2008

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Washington D.C., District of Columbia, United States +7 more locations

TERMINATEDPhase 3629 miles

GALLANT 6 Tesaglitazar vs. Pioglitazone

NCT00214565

This is a 24-week randomized, double-blind, multi-center, active-controlled (pioglitazone) study of tesaglitazar (0.5 mg and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 3-week enrollment period, 6 week placebo single blind run in period followed by a 24-week double blind treatment period and a 3-week follow-up period.

Diabetes Mellitus, Type 2

AstraZeneca1,450 participantsStarted Aug 2004

Altoona, Pennsylvania, United States • Ciudad de Buenos Aires, Argentina • Córdoba, Argentina +71 more locations

TERMINATEDPhase 1/2662 miles

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I

NCT00439218

The purpose of this study is to identify the maximum tolerated dosage of sodium phenylbutyrate in children with spinal muscular atrophy type I; and to determine if the drug has an effect on SMN mRNA and protein levels.

Spinal Muscular Atrophy Type I

Westat5 participantsStarted Jan 2008

Stanford, California, United States • Boston, Massachusetts, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 3699 miles

A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)

NCT00225589

The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.

Hypercholesteremia

AstraZeneca840 participantsStarted Aug 2002

Alhambra, California, United States • La Jolla, California, United States • Los Angeles, California, United States +54 more locations

COMPLETEDNA812 miles

Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles

NCT00928057

Anxiety about needles is a commonly expressed concern by diabetics about beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of currently marketed pen needles may appeal to many diabetic patients as the new needle may be perceived as less intimidating and more comfortable. Currently marketed pen needles range in length from 5 to 12.7 millimeters (mm). The primary purpose of this study was to evaluate whether the investigational 4mm x 32 Gauge(G) pen needle manufactured by Becton, Dickinson and Company (BD) provides equivalent glucose control (as measured by fructosamine levels) as the currently marketed BD 5mm x 31 G and BD 8mm x 31 G pen needles (PN)in diabetic subjects with varying insulin dosage regimens.

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Becton, Dickinson and Company173 participantsStarted Jun 2009

Birmingham, Alabama, United States • Escondido, California, United States • Atlanta, Georgia, United States +1 more locations

COMPLETEDPhase 1830 miles

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

NCT00083135

RATIONALE: Giving iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) may kill neuroblastoma cells by delivering radiation directly to the tumor. A stem cell transplant using the patient's stem cells may be able to replace blood-forming cells destroyed by radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of a double infusion of \^131I-MIBG followed by autologous stem cell transplantation in treating patients with refractory neuroblastoma.

Children's Hospital Los Angeles18 participantsStarted Mar 2004

Los Angeles, California, United States • San Francisco, California, United States • Indianapolis, Indiana, United States +4 more locations

COMPLETEDPhase 4896 miles

SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe

NCT00402272

The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery lesions.

Coronary DiseaseCoronary Artery DiseaseCoronary Restenosis

Abbott Medical Devices2,700 participantsStarted Nov 2006

Salzburg, Austria • Brussels, Belgium • Brussels, Belgium +90 more locations

TERMINATEDPhase 2938 miles

Long Term Open Follow-up With H376/95 vs. Warfarin

NCT00206063

The purpose of this study is to evaluate tolerability of long-term treatment with ximelagatran compared to standard treatment with warfarin.

Stroke Prevention in Patients With Atrial Fibrillation

AstraZeneca220 participantsStarted Aug 1999

Palo Alto, California, United States • Oostduinkerke, Belgium • Helsingor, Czechia +16 more locations

PreviousPage 869 of 909Next

Heart Diseasein Denver